Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978323 | 0.84 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL4718434 | 0.84 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL6646578 | 0.80 | ACE (0.31) | KMT2A | |
| SCHEMBL16494534 | 0.76 | BRD4 (0.44) | BRD4CYP1A2HIF1AALDH1A1FKBP1A | |
| SCHEMBL7022793 | 0.74 | BRD4 (0.37) | BRD4SMN1; SMN2CYP1A2HIF1AALDH1A1 | |
| SCHEMBL16495148 | 0.71 | BRD4 (0.40) | BRD4SMN1; SMN2CYP1A2HIF1AALDH1A1 | |
| SCHEMBL10818686 | 0.70 | BRD4 (0.39) | BRD4SMN1; SMN2CYP1A2HIF1AALDH1A1 | |
| SCHEMBL6098996 | 0.69 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1KDM4EHSD17B10POLB | |
| SCHEMBL2597463 | 0.69 | BRD4 (0.45) | BRD4CYP1A2HIF1AALDH1A1KDM4E | |
| SCHEMBL8394065 | 0.68 | FKBP1A (0.36) | BRD4CYP1A2HIF1AKDM4EFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| US-7576095-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| WO-2008120000-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-20080009513-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009513-A1 | Therapeutic agents | NLN, GPR119, FABP4 | BRD4 1346/4885SMN1; SMN2 275/4885CYP1A2 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.